Literature DB >> 19934211

Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia.

Colm M P O'Tuathaigh1, Brian P Kirby, Paula M Moran, John L Waddington.   

Abstract

Negative symptoms encompass diminution in emotional expression and motivation, some of which relate to human attributes that may not be accessible readily in animals. Additionally, their refractoriness to treatment precludes therapeutic validation of putative models. This review considers critically the application of mutant mouse models to the study of the pathobiology of negative symptoms. It focuses on 4 main approaches: genes related to the pathobiology of schizophrenia, genes associated with risk for schizophrenia, neurodevelopmental-synaptic genes, and variant approaches from other areas of neurobiology. Despite rapid advances over the past several years, it is clear that we continue to face substantive challenges in applying mutant models to better understand the pathobiology of negative symptoms: the majority of evidence relates to impairments in social behavior, with only limited data relating to anhedonia and negligible data concerning avolition and other features; even for the most widely examined feature, social behavior, studies have used diverse assessments thereof; modelling must proceed in cognizance of increasing evidence that genes and pathobiologies implicated in schizophrenia overlap with other psychotic disorders, particularly bipolar disorder. Despite the caveats and challenges, several mutant lines evidence a phenotype for at least one index of social behavior. Though this may suggest superficially some shared relationship to negative symptoms, it is not yet possible to specify either the scope or the pathobiology of that relationship for any given gene. The breadth and depth of ongoing studies in mutants hold the prospect of addressing these shortcomings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19934211      PMCID: PMC2833123          DOI: 10.1093/schbul/sbp125

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  203 in total

1.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

2.  Automation of the social interaction test by a video-tracking system: behavioural effects of repeated phencyclidine treatment.

Authors:  F Sams-Dodd
Journal:  J Neurosci Methods       Date:  1995-07       Impact factor: 2.390

3.  Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons.

Authors:  S Takamori; J S Rhee; C Rosenmund; R Jahn
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

4.  Specific modulation of social memory in rats by cholinomimetic and nootropic drugs, by benzodiazepine inverse agonists, but not by psychostimulants.

Authors:  A Perio; J P Terranova; P Worms; R M Bluthe; R Dantzer; K Biziere
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 5.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence.

Authors:  P J Harrison; D R Weinberger
Journal:  Mol Psychiatry       Date:  2005-01       Impact factor: 15.992

Review 6.  Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology.

Authors:  Peter F Whitty; Olabisi Owoeye; John L Waddington
Journal:  Schizophr Bull       Date:  2008-09-12       Impact factor: 9.306

Review 7.  Ultrasonic vocalizations: a tool for behavioural phenotyping of mouse models of neurodevelopmental disorders.

Authors:  Maria Luisa Scattoni; Jacqueline Crawley; Laura Ricceri
Journal:  Neurosci Biobehav Rev       Date:  2008-08-13       Impact factor: 8.989

8.  Genetic associations with schizophrenia: meta-analyses of 12 candidate genes.

Authors:  Jiajun Shi; Elliot S Gershon; Chunyu Liu
Journal:  Schizophr Res       Date:  2008-08-20       Impact factor: 4.939

Review 9.  Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review.

Authors:  James M Stone; Paul D Morrison; Lyn S Pilowsky
Journal:  J Psychopharmacol       Date:  2007-01-26       Impact factor: 4.153

Review 10.  Is COMT a susceptibility gene for schizophrenia?

Authors:  Hywel J Williams; Michael J Owen; Michael C O'Donovan
Journal:  Schizophr Bull       Date:  2007-04-04       Impact factor: 9.306

View more
  23 in total

Review 1.  The role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy.

Authors:  Holly Moore
Journal:  Schizophr Bull       Date:  2010-09-24       Impact factor: 9.306

Review 2.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

3.  Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and imaging measures.

Authors:  Daniel H Wolf; Theodore D Satterthwaite; Jacob J Kantrowitz; Natalie Katchmar; Lillie Vandekar; Mark A Elliott; Kosha Ruparel
Journal:  Schizophr Bull       Date:  2014-03-22       Impact factor: 9.306

4.  Anxiety does not contribute to social withdrawal in the subchronic phencyclidine rat model of schizophrenia.

Authors:  Alexandre Seillier; Andrea Giuffrida
Journal:  Behav Pharmacol       Date:  2017-10       Impact factor: 2.293

5.  Tumour necrosis factor-mediated homeostatic synaptic plasticity in behavioural models: testing a role in maternal immune activation.

Authors:  Sarah C Konefal; David Stellwagen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-03-05       Impact factor: 6.237

Review 6.  Animal models of schizophrenia.

Authors:  C A Jones; D J G Watson; K C F Fone
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 7.  Preclinical models of antipsychotic drug action.

Authors:  José L Moreno; Javier González-Maeso
Journal:  Int J Neuropsychopharmacol       Date:  2013-06-10       Impact factor: 5.176

8.  Neural mechanisms underlying stress resilience in Ahi1 knockout mice: relevance to neuropsychiatric disorders.

Authors:  A Lotan; T Lifschytz; A Slonimsky; E C Broner; L Greenbaum; S Abedat; Y Fellig; H Cohen; O Lory; G Goelman; B Lerer
Journal:  Mol Psychiatry       Date:  2013-09-17       Impact factor: 15.992

9.  SorCS2 is required for BDNF-dependent plasticity in the hippocampus.

Authors:  S Glerup; U Bolcho; S Mølgaard; S Bøggild; C B Vaegter; A H Smith; J L Nieto-Gonzalez; P L Ovesen; L F Pedersen; A N Fjorback; M Kjolby; H Login; M M Holm; O M Andersen; J R Nyengaard; T E Willnow; K Jensen; A Nykjaer
Journal:  Mol Psychiatry       Date:  2016-07-26       Impact factor: 15.992

10.  Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: Possible involvement of the endocannabinoid system.

Authors:  Alexandre Seillier; Andrea Giuffrida
Journal:  Eur Neuropsychopharmacol       Date:  2015-12-10       Impact factor: 4.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.